ABSTRACT
Objective To investigates the diagnostic value of combined detection serum CCL18, CXCL1 antigen, C1D, TM4SF1, FXR1, TIZ IgG autoantibody by suspension array for ovarian cancer. Methods Suspension array was used to detect CCL18, CXCL1 antigen, C1D, TM4SF1, FXR1, TIZ IgG autoantibody in 120 cases of healthy women, 204 cases of patients with benign pelvic tumors, 119 cases of pelvic malignant tumor patients, and 40 cases with breast cancer, lung cancer oroliver cancer, respectively. Constructed diagnosis model of combined detection six biomarkers for diagnosis of ovarian malignant tumor. Constructed diagnosis model of combined detection autoantibodies to diagnose epithelial ovarian cancer. Analysed the value of detecting six biomarkers for diagnosis of ovarian malignant tumor and detecting autoantibodies for diagnosis of epithelial ovarian cancer. Analysed diagnostic value of detecting six biomarkers to diagnose stageⅠandⅡepithelial ovarian cancer. Compared diagnostic value of detecting six biomarkers in diagnosis of tissue types and pathologic grading with that of CA125. Results Model of combined detecting six biomarkers to diagnose ovarian malignant tumor was logit(P)=-11.151+0.008×C1D+0.011 × TM4SF1+0.011 × TIZ-0.008 × FXR1+0.021 × CCL18+0.200 × CXCL1. Model of combined detection autoantibodies to diagnose epithelial ovarian cancer was logit(P)=-5.137+0.013 × C1D+0.014 × TM4SF1+0.060 × TIZ-0.060 × FXR1. Sensitivity and specificity of detecting six biomarker to diagnose ovarian malignant tumor was 90.6% and 98.7%. Sensitivity and specificity of detecting autoantibodies to diagnose epithelial ovarian cancer was 75.8%and 96.7%. Combined detection for six biomarkers to diagnose serous and mucinous ovarian cancer was statistically no better than those of CA125 (P=0.196 and P=0.602, respectively);there was significantly difference in diagnosis of ovarian cancer (P=0.023), and there was no significantly difference in diagnosis of different pathological grading (P=0.089 and P=0.169, respectively). Conclusions Constructing diagnosis model of combined detection six biomarker to diagnose ovarian malignant tumor and constructed diagnosis model of combined detectionautoantibodies to diagnose epithelial ovarian cancer. Combined detection six biomarkers to diagnose serous and mucinous ovarian tumors is better than that of CA125.
ABSTRACT
Objective To investigate the effect of growth,invasion and metastasis on ovarian cancer cell line SKOV3 with chemokine (C-C motif) ligand 18 (CCL18) over-expression by mediated in vitro.Methods The restructuring plasmid of CCL18 expression was constructed and SKOV3 cells was transfected with plasmid DNA in vitro.The growth curve,cell cycle,cell migration,invasion and adhesion capacity in SKOV3-CCL18 cells and control cells were detected by methyl thiazolyl tetrazolium (MTT) assay,flow cytometry,transwell chamber,migration invasion and fibronectin adhesion method,respectively.Results (1) CCL18-pEGFP-N1 plasmid was successfully constructed and transmitted to the SKOV3 cells,the stable growth of the subculture SKOV3-CCL18 cells was screening and completed.(2) Compared with SKOV3-CCL18 cells and SKOV3 or SKOV3-pEGFP-N1 cells,there was not differences statistically significant in growth curve (all P ＞ 0.05) ; but the rate of the SKOV3-CCL18 cells in a proliferative field (S + G2 + M) was significantly higher than that in SKOV3 or SKOV3-pEGFP-N1 cells (32.80％ versus 27.06％,32.80％ versus 26.98％,respectively; all P ＜ 0.05).(3) The invasion,migration and adhesion capacity of SKOV3-CCL18 cells (being 0.49 ± 0.18,1.16 ± 0.25 and 0.39 ± 0.10,respectively) in vitro were significantly higher than those in SKOV3 (being 0.23 ± 0.13,0.36 ± 0.10 and 0.16 ± 0.03,respectively) or SKOV3-pEGFP-N 1 cells (being 0.19 ± 0.05,0.38 ± 0.23 and 0.13 ± 0.11,respectively; all P ＜ 0.05).Conclusion The CCL18 over-expression in epithelial ovarian cancer SKOV3 cells could lead to strengthen ability of invasion,migration and adhesion in vitro.
ABSTRACT
Objective To investigate the role of CC chemokine ligand 20 (CCL20) and CC chemokine receptor 6 (CCR6) in the pathogenesis of acute necrotizing pancreatitis (ANP). Methods 48 SD rats were randomly divided into two groups: control group and ANP group. The ANP model was induced by retrograde infusion of 4 % sodium taurocholate into the biliary and pancreatic duct in SD rats. The same amount of saline was injected in the control group. The rats were sacrificed at 1, 3, 6, 12 h, the serum amylase levels and the pathological score of the pancreas were measured. The expressions of CCL20 and CCR6 mRNA and protein in pancreas were detected by immunohistochemistry and semi-quantitative RT-PCR,respectively. Results The levels of serum amylase and the histological score of ANP group were significantly higher than those of control group (P ＜ 0.01 ). The expression of pancreatic CCL20 mRNA and protein was increased in a time-dependant manner ( P ＜ 0.05 ). The expression of pancreatic CCR6 mRNA at 6h was significantly higher than that of control group (0.88 ± 0.05 vs 0. 23 ± 0.09, P ＜ 0.01 ). The expression of pancreatic CCR6 mRNA at 12h was decreased when compared with that of 6h group, but it was still higher than that of control group (0.37 ± 0. 10 vs 0. 15 ± 0.07, P ＜ 0.05 ), the change of CCR6 protein was consistent with that of CCR6 mRNA. Conclusions CCL20 and CCR6 may play an important role in the pathogenesis of ANP.
ABSTRACT
CCL21 is originally reported as a CC chemokine mainly expressed in secondary lymphoid tissues. CCL21 can dictate lymphocytes homing in the flow environment,where T cells use integrins stimulated by CCL21 to arrest on endothelial cells,and can act as a chemoattractant for T cells,B cells,mature dentritic cells and natural killer cells strongly. CCL21 can collect activated effector cells and keep them around the tumor. It is also a pivotal molecule for priming T cell responses. Therefore,CCL21 plays a potential role in anti-tumor therapy, and its high expression is responsible for many immune diseases.
ABSTRACT
Objective To determine the serum level of chernokine CCL27 in patients with psoriasis vulgaris,and to analyse its clinical relevance.Methods A total of 61 patients(40 in progressive stage and 21 in stable stage)with psoriasis vulgaris,with an average disease duration of 37.97±14.34 years,were included in this study.Appropriate thempy was given to these patients.Serum samples were collected from the patients before and after therapy,as well as from 45 healthy human controls.ELISA was applied to examine the serum concentration of CCL27.Clinical severity of psoriasis vulgaris was assessed by psoriasis area and severity index(PASI)score.Results Serum level of CCL27 was 670.02±262.15 ng/L in psoriatic patients,compared to 373.10±92.84 ng/L in the controls(t=8.18.P＜0.01).Increased serum level of CCL27 was observed in patients with progressive psoriasis vulgaris compared to those with stable psoriasis (799.94±214.54 ng/L vs 422.57±135.53 ng/L,t=8.39,P＜0.01).After 8 weeks of therapy,a significant decrease was noticed in the serum level of CCL27 in patients who experienced≥70%reduction in PASI score(t=9.95,P＜0.01).but not in those experiencing a PASI reduction of＜70%(t=1.84,P＞0.05).The serum level of CCL27 was positively correlated with PASI score(r=0.58,P＜0.01).Conclusions The serum level of CCL27 is significantly elevated in patients with psoriasis vulgaris,and it is correlated with the disease severity.
ABSTRACT
Objective To study the production and distribution of vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein 1 (MCP-1) in the skin and sera of patients with psoriasis and their roles in the pathogenesis of psoriasis. Methods Levels of VEGF and MCP-1 in sera were measured using double antibody sandwich enzyme linked immunosorbent assay(ELISA) in patients with psoriasis. The expression and distribution of VEGF and MCP-1 in psoriatic lesions, non lesional skin and normal controls were detected by immunohistochemical method. Results ①The expression of VEGF in lesional skin and non lesional skin of psoriasis patients was higher than that in normal controls. Levels of MCP-1 were increased in lesional skin than those in non lesional skin and normal controls.②Serum levels of VEGF were significantly increased in psoriasis as compared with normal control. There was no significant difference in serum levels of MCP-1 between patients and controls.③There was no correlation between the expression of MCP-1 or VEGF of psoriatic lesion and PASI index. Conclusion Overexpression of two cytokines, VEGF and MCP-1, known to promote new blood vessel formation may contribute to the pathogenesis of psoriasis.
ABSTRACT
Objective To investigate the mRNA expression of CC Chemokines, including RANTES (regulated upon activation, normal T cell expressed and secreted), monocyte chemoattracctant protein-1 (MCP-1), monocyte chemoattracctant protein-3 (MCP-3) and macrophage inhibitory protein 1? (MIP-1?), in peripheral blood mononuclear cells (PBMCs) of patients with chronic urticaria, their mutual correlation, and the relationship between the expression level of CC chemokines and the serum level of IgE and eosinophil cationic protein (ECP) in the patients. Methods Reverse transcription-polymerase reaction (RT-PCR) was applied to semiquantitatively analyze the mRNA expression of RANTES, MCP-1, MCP-3 and MIP-1? in PBMCs from 31 patients with chronic urticaria and 22 healthy subjects. Results The mRNA expression of RANTES, MCP-1, MCP-3 and MIP-1?was significantly higher in the patients than those in the normal controls (P 0.05). In the patients, the mRNA expression of RANTES negatively correlated with the serum level of IgE and ECP (P